HES-SO Valais-Wallis Launches Innovative Digital Life Sciences Program
Exclusive program in French-speaking Switzerland combines life sciences expertise with advanced digital skills to meet industry demands
Exclusive program in French-speaking Switzerland combines life sciences expertise with advanced digital skills to meet industry demands
Founded in 2012 at the BioArk technology site in Monthey and supported by the Ark Foundation’s incubator during its start-up phase, CordSavings is now establishing itself as a major player in the field of umbilical cord stem cell preservation. Combining scientific expertise and ethical commitment, CordSavings is also the only private biobank in Switzerland, offering pregnant women and all families expecting a child the opportunity to collect and store stem cells in Switzerland.
Lonza strengthens its bioconjugation capacities at Visp, in the canton of Valais, with two new manufacturing suites.
Final deadline for submitting applications to the Innosuisse call for projects for the Flagship Initiative 2024, focusing on Artificial Intelligence in Life Sciences, with an emphasis on healthcare.
Precise Health, a biotech start-up based at the Energypolis Campus in Sion, has just won phase 2 of the national Venture Kick competition. The CHF 40,000 prize will enable the company to further develop its technology, which is revolutionizing the treatment of antibiotic-resistant bacterial infections.
Lonza is expanding its partnership with an undisclosed major pharmaceutical company to supply antibody-drug conjugates (ADCs). This agreement includes building a new facility at Lonza’s Ibex® Biopark in Visp (Valais), Switzerland, and providing large-scale production of monoclonal antibodies for a new ADC treatment.
From lab bench to pitch perfection : Ninsun’s cancer-fighting innovation just lit up the Innothèque at Foire du Valais last Friday for the Startup Pitch of the Fondation the Ark !
The “Innovation in the vineyards” event, held on September 30th at the Innothèque space during the Foire du Valais, was a resounding success, attracting over thirty participants. Organized in collaboration with PhytoArk, this event highlighted the technological advancements and innovations transforming the viticulture sector.
On 23 September 2024, ten23 health celebrated the inauguration of its VIVA2® facility in Visp, in the vicinity of our BioArk Visp technology site, bringing to fruition an ambitious project announced in June 2022. This new state-of-the-art infrastructure considerably strengthens the region’s production capacity for sterile medicines.
Swiss contract development and manufacturing organization ten23health has achieved B Corp certification, recognizing its commitment to social and environmental responsibility in the pharmaceutical industry.